Endo shutters a pain program following trial failure

There will be no third act for Endo's pain drug partnership with Grunenthal. Endo had originally signed on to the pact in early 2009, gaining U.S. marketing rights to axomadol. But earlier this summer investigators reported the disappointing news that the drug had failed a mid-stage study, and this morning the biotech company said it will shutter the program and dump the collaboration. Story

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.